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BRCA1 and BRCA2 facilitate replication
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forming potential, including telomeres,
and suppress genomic instability
stemming from inefficient replication of
these sites. G4-stabilizing compounds
are toxic to BRCA1- and BRCA2-deficient
cells, highlighting their therapeutic
potential in targeting BRCA deficiency.
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G-quadruplex (G4)-forming genomic sequences, in-
cluding telomeres, represent natural replication fork
barriers. Stalled replication forks can be stabilized
and restarted by homologous recombination (HR),
which also repairs DNA double-strand breaks (DSBs)
arising at collapsed forks. We have previously shown
that HR facilitates telomere replication. Here, we
demonstrate that the replication efficiency of gua-
nine-rich (G-rich) telomeric repeats is decreased
significantly in cells lacking HR. Treatment with
the G4-stabilizing compound pyridostatin (PDS) in-
creases telomere fragility in BRCA2-deficient cells,
suggesting that G4 formation drives telomere insta-
bility. Remarkably, PDS reduces proliferation of HR-
defective cells by inducingDSBaccumulation, check-
point activation, and deregulated G2/M progression
and by enhancing the replication defect intrinsic to
HR deficiency. PDS toxicity extends to HR-defective
cells that have acquired olaparib resistance through
loss of 53BP1 or REV7. Altogether, these results high-
light the therapeutic potential of G4-stabilizing drugs
to selectively eliminate HR-compromised cells and
tumors, including those resistant to PARP inhibition.
INTRODUCTION
Genomic instability is a hallmark of cancer caused by failure of
normal DNA replication and/or repair mechanisms (HalazonetisMoet al., 2008; Negrini et al., 2010). During replication, the enzy-
matic activities of DNA polymerases, helicases, and nucleases
act in concert to assemble the active replication fork and to
achieve high-fidelity duplication of the genome. Damaged
DNA, secondary DNA structures, and DNA-protein complexes
obstruct progression of replication forks, leading to fork stalling
or, in more severe cases, to irreversible fork collapse and DNA
breakage. Several mechanisms have evolved to overcome
barriers to replication-fork movement, one of which exploits
the HR DNA repair machinery. HR factors act to stabilize stalled
replication forks by preventing their nucleolytic degradation (Ha-
shimoto et al., 2010; Schlacher et al., 2011) to restart arrested
forks (Lambert et al., 2010) and to repair double-strand breaks
(DSBs) arising from disintegrated forks (Aze et al., 2013).
The tumor suppressor BRCA2 is a key component of the HR
pathway of DSB repair. BRCA2 promotes recombination reac-
tions by loading the RAD51 recombinase onto single-stranded
DNA (ssDNA) in concert with the family of proteins known as
the RAD51 paralogs, of which RAD51C is a member (Suwaki
et al., 2011). RAD51-coated ssDNA invades an intact, homolo-
gous duplex DNA molecule, most commonly a sister chromatid,
which becomes the template for accurate DSB repair.
In vitro, G-rich ssDNA can adopt secondary structures known
as G4s under physiological-like conditions (Lipps and Rhodes,
2009). G4s consist of stacks of two or more G-quartets formed
by four guanines via Hoogsteen base pairing stabilized by a
monovalent cation. While in silico analyses have identified
more than 300,000 sites with G4-forming potential in the human
genome (Huppert and Balasubramanian, 2005), more recent
G4-seq approaches enabled detection of more than 700,000
G4 structures genome-wide (Chambers et al., 2015). The first
in vitro visualization of a G4 structure was based on diffractionlecular Cell 61, 449–460, February 4, 2016 ª2016 The Authors 449
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Figure 1. RAD51C and BRCA2 Prevent Lag-
ging-Strand Telomere Fragility
(A and B) Replication efficiency of a plasmid con-
taining (TTAGGG)7 in H1299 cells expressing
doxycycline (DOX)-inducible RAD51C (A) or
BRCA2 (B) shRNAs is shown relative to the repli-
cation efficiency of the empty vector (n = 3 for
RAD51CshDOX; n = 4 for BRCA2shDOX; error bars,
SEM). p values were calculated using a one-
sample t test (*p % 0.05 and ***p % 0.001). Cell
extracts prepared at the time of plasmid trans-
fection were immunoblotted as indicated. GAPDH
and SMC1 were used as loading controls.
(C) CO-FISH detection of lagging (G-rich, green)
and leading (C-rich, red) telomeric strands in
immortalized Rad51cF/F MEFs treated with Cre
(+Cre) and control (Cre) retroviruses. Enlarged
inset shows the area marked with the yellow
rectangle. Arrows mark lagging-strand fragile
telomeres.
(D and E) Quantification of fragile telomeres in
immortalized Rad51cF/F (D) and Brca2F/- (E) MEFs.
Approximately 1,000 telomeres were scored per
condition per replica (n = 2; error bars, SD). See
also Figure S1.patterns of a guanylic acid solution (Gellert et al., 1962), while ev-
idence that G4s assemble in vivo initially came from
immunostaining of Stylonychia macronuclei with antibodies
raisedagainstG4structureswith telomeresequences (Schaffitzel
et al., 2001). This study demonstrated that telomeres adopt a
G4 configuration in vivo. G4 structures have been subsequently
detected with several other structure-specific antibodies (Biffi
et al., 2013; Henderson et al., 2014; Schaffitzel et al., 2001) and
interacting small molecules (Lam et al., 2013; Mu¨ller et al., 2010;
Rodriguez et al., 2012). Importantly, telomeric G-rich DNA se-
quences have a high propensity to adopt G4 configurations
(Parkinson et al., 2002). Telomeres, repetitive DNA sequences
bound by the protein complex shelterin, protect chromosome
ends from degradation and fusion. Telomeric G4s can interfere
with telomere replication, leading to fragile, shorter telomeres.
Supporting this concept, treatment with G4-stabilizing com-
pounds induces telomere dysfunction (Gomez et al., 2006;
Rodriguez et al., 2008; Salvati et al., 2007; Tahara et al., 2006).
During DNA replication, G4s are thought to assemble sponta-
neously on G-rich ssDNA displaced during fork movement. Due
to their thermodynamic stability, G4s cause uncoupling of repli-
some components and fork stalling, which have the potential to
trigger genomic instability. Helicases such as FANCJ, PIF1,
RECQ, BLM, and WRN, the chromatin remodeler ATRX, and
the REV1 translesion polymerase act to dismantle G4s in vitro.
Several lines of evidence support a similar function in vivo for
these factors, essential to preserve genome stability during
DNA replication (Murat and Balasubramanian, 2014). Con-
versely, G4 configurations can be stabilized by specific ligands
that exhibit higher binding specificity for G4s over duplex DNA,
with the G4-interacting compound PDS being one example
(Chambers et al., 2015). In mammalian cells, G4 stabilization
by PDS results in dissociation of shelterin components from telo-
meres (Rodriguez et al., 2008). More recently, PDS was demon-
strated to trigger replication- and transcription-associated DNA450 Molecular Cell 61, 449–460, February 4, 2016 ª2016 The Authordamage at genomic sites with predicted G4-forming potential
(Lam et al., 2013; Rodriguez et al., 2012). These findings highlight
the deleterious consequences of persistent G4s for telomere and
genome integrity.
HR factors, including BRCA2 and RAD51, are required to facil-
itate telomere replication and to prevent telomere shortening
(Badie et al., 2010). It remained unclear, however, whether as-
sembly of telomeric G4s could contribute to the telomere replica-
tiondefectofHR-deficient cells. In thiswork,wedemonstrate that
telomere fragility in cells lacking HR repair is enhanced by PDS
treatment. Importantly, G4-stabilizing compounds, including
PDS, decrease the viability of BRCA1-, BRCA2-, or RAD51-defi-
cient cells, which is associated with elevated levels of DNA
damage and replication stress. We suggest that in the context
of HR deficiency, persistent G4 structures exacerbate the cell-
intrinsic challenges that arise during replication of regions with
G4-forming potential, thus eliciting checkpoint activation, G2/M
cell-cycle arrest, and cell death. This work is therefore highly rele-
vant to the search for treatments that selectively kill tumor cells
whose capacity for HR-mediated repair has been compromised.
RESULTS
BRCA2 and RAD51C Are Required for G-Rich Strand
Telomere Replication
Abrogation of key HR activities elicits telomere fragility (Badie
et al., 2010) suggestive of a role for HR in telomere replication.
To further investigate this concept, we used a plasmid-based
replication assay (Szu¨ts et al., 2008) in H1299 cells harboring
inducible small hairpin RNA (shRNA) against RAD51C or
BRCA2. Doxycycline addition induced efficient depletion of
both proteins, as determined by western blotting (Figures 1A
and 1B). The replication efficiency of a plasmid containing an
array of seven telomeric repeats (TTAGGG)7 was significantly
lower in RAD51C- or BRCA2-deficient cells compared to controls
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Figure 2. Effect of the G4-Interacting Com-
pound PDS on Telomere Fragility and
Viability of Brca-Deficient MEFs
(A) Mitotic chromosome spreads of p53/ MEFs
grown in the presence (+PDS) or absence (PDS)
of 5 mMPDS for 48 hr. Preparations were fixed and
stained with anti-gH2AX monoclonal antibody
(green). Telomeres were visualized with a Cy3-
conjugated (CCCTAA)6-PNA probe (red), using
identical exposure conditions for untreated and
PDS-treated cells. DNA was counterstained with
DAPI (blue).
(B) Quantification of fragile telomeres visualized by
FISH on metaphase chromosomes from Brca2F/-
MEFs treated with Cre (+Cre) and control (Cre)
retroviruses incubated with 5 mM PDS for 40 hr
(n = 2; > 1,500 long-arm telomeres were scored
per condition per replica; error bars, SD). p values
were calculated using an unpaired two-tailed t test
(*p% 0.05).
(C) Dose-dependent viability assays of Brca2F/-
MEFs treated with Cre (+Cre) and control (Cre)
retroviruses exposed to PDS or olaparib at the
indicated concentrations.
(D) Dose-dependent viability assays of Brca1F/-
MEFs treated as in (C).
(E) Dose-dependent viability assays of immortal-
ized (imm.) MEFs treated as in (C) with retroviruses
encoding shRNA against GFP or 53BP1 (Bouw-
man et al., 2010). Cell extracts were immuno-
blotted as indicated. SMC1 was used as a loading
control. See also Figures S1 and S2. Graphs
shown are representative of at least two inde-
pendent experiments, each performed in triplicate.
Error bars represent SD of triplicate values ob-
tained from a single experiment.cells (Figures 1A and 1B). RAD51C inhibition did not affect cell
proliferation rate (Figure S1A, available online). Full-length
human RAD51C rescued the telomere replication defect
completely, indicating specificity of the shRNA for its target (Fig-
ure S1B). Importantly, replication of a plasmid containing a
(TTACGC)7 sequence, with two G-to-C substitutions in the telo-
mere repeat, which abrogate the G4-forming potential of the
sequence, was not affected by loss of RAD51C expression
(Figure S1C). Collectively, these data suggest that assembly of
G4 secondary structures on the telomere-containing plasmid
underlines its inefficient replication in BRCA2- or RAD51C-
depleted cells.
We previously reported that Brca2 or Rad51c deletion in
mouse embryonic fibroblasts (MEFs) leads to increased levels
of multiple telomeric fluorescence in situ hybridization (FISH) sig-
nals (Badie et al., 2010), indicative of telomere fragility. To
examine the specificity of the fragile telomere phenotype to the
leading or lagging-strand template, chromosome orientation
FISH (CO-FISH) assays were performed in immortalized Brca2F/-
or Rad51cF/F MEFs, in which gene deletion was induced with
‘‘hit-and-run’’ Cre recombinase. The telomeric G-rich strand
showed a clear propensity for FISH signal fragmentation (Fig-
ure 1C, green). Quantification of fragmented telomeric CO-
FISH signals further demonstrated the bias toward fragility of
the G-rich telomeric strand in Cre-treated Brca2F/- andMoRad51cF/F MEFs (Figures 1D and 1E) as well as in a Brca2/
mouse mammary tumor-derived cell line (Evers et al., 2010;
Figure S1D).
G4 Structure Stabilization Exacerbates the Telomere
Fragility in Brca2-Deleted MEFs
Telomere fragility indicates a telomere replication defect (Martı´-
nez et al., 2009; Sfeir et al., 2009), which is thought to stem
from the potential of telomere DNA sequences to adopt G4 sec-
ondary structures known to obstruct replication fork progres-
sion. To test whether telomere fragility in HR-deficient cells
was linked to G4 formation, we used the G4 ligand PDS (Rodri-
guez et al., 2008, 2012) to treat p53/ MEFs, which are known
to proliferate in the presence of DNA damage, followed by immu-
nofluorescence combined with telomere FISH (IF-FISH) detec-
tion. Exposure to PDS led to accumulation of nuclear foci of
the Ser139-phosphorylated form of histone H2AX (gH2AX, Fig-
ure 2A), a well-established DSB marker. A subset of these foci
colocalized with chromosome ends (Figure 2A, yellow arrow-
heads), while others localized intrachromosomally (Figure 2A,
gray arrowheads). A similar PDS effect has been reported in hu-
man cells (Rodriguez et al., 2012). In addition, PDS triggered a
dramatic reduction in the intensity of telomere FISH signals cor-
responding to the G-rich telomere strand (Figures 2A and S1E).
In these images, the same exposure time was used for imagelecular Cell 61, 449–460, February 4, 2016 ª2016 The Authors 451
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Figure 3. Effect of PDS on BRCA2- or RAD51-Deficient Human Cell
Viability
(A and B) Dose-dependent viability assays of DLD1 cells, BRCA2 proficient
(+BRCA2) or deficient (BRCA2), treated with indicated concentrations of
PDS (A) or olaparib (B).
(C–E) Dose-dependent viability assays of HEK293T cells transfected with
control or RAD51 siRNA treated with indicated concentrations of PDS (C),
olaparib (D), or PhenDC (E). Graphs shown are representative of at least two
independent experiments, each performed in triplicate. Error bars represent
SD of triplicate values obtained from a single experiment.
(F) Whole-cell extracts prepared after 4 days of treatment with 2 mM PDS or
PhenDC (PhDC) were immunoblotted as indicated. Tubulin was used as a
loading control. See also Figure S2.acquisition of untreated and PDS-treated cells, to enable com-
parison of the telomeric signal intensity between the two sam-
ples. In contrast, in Figure 2B the exposure time was increased
when acquiring images of PDS-treated samples (but not in un-
treated controls) in order to compensate for the reduced
telomeric FISH signal and to enable quantification of fragile telo-
meres. G4 stabilization significantly enhanced the telomere
fragility characteristic of Brca2-deleted MEFs (Figure 2B), sug-
gesting that persistent G4 structures contribute to the telomere
replication defect intrinsic to cells lacking BRCA2.
We next monitored the viability of Brca2-deleted MEFs grown
in the presence of PDS or poly (ADP-ribose) polymerase 1
(PARP1) inhibitor olaparib. Even though PDS was moderately
toxic to BRCA2-proficient MEFs, we detected a more prominent
dose-dependent reduction in the viability of Cre-treated Brca2F/-
MEFs exposed to this compound or olaparib (Figure 2C). The
same specific elimination by PDSwas observed for BRCA2-defi-
cient V-C8 hamster cells (Kraakman-van der Zwet et al., 2002;
Figure S2A) and Brca2/ mouse mammary tumor-derived cells
(Figure S2B).
The tumor suppressor BRCA1 plays a key role in HR by
promoting end resection, which enables loading of the RAD51
recombinase and initiation of HR-mediated repair. This activity
of BRCA1 is antagonized by 53BP1, which protects broken
DNA ends and channels their repair into non-homologous end
joining (NHEJ) (Bouwman et al., 2010; Bunting et al., 2010). To
address whether NHEJ deficiency also sensitizes cells to G4
stabilizing agents, similarly to HR ablation, we tested whether
Brca1 or 53BP1 loss confers sensitivity to PDS. Only viability of
Brca1-deleted cells was affected by exposure to PDS (Figures
2D and 2E), suggesting that G4 stabilization is specifically toxic
to HR-, but not to NHEJ-compromised cells. A similar HR-spe-
cific effect was observed in response to olaparib (Figures 2D
and 2E).
G4-Interacting Compounds Specifically Kill HR-
Deficient Human Cells
To investigate whether PDS-induced G4 stabilization affects
viability of human cells lacking BRCA2, we used a matched
pair of BRCA2-proficient and deficient DLD1 colorectal adeno-
carcinoma cell lines (Hucl et al., 2008). Exposure of BRCA2-
deficient DLD1 cells to PDS led to a marked decrease in viability
compared to BRCA2-proficient cells within 3 days (Figure S2C),
which became more pronounced after six days of treatment
(Figure 3A). The PARP1 inhibitor olaparib was used as a control
in these experiments based on its ability to preferentially kill
BRCA2-deficient cells (Figure 3B). Importantly, PDS toxicity
to cells lacking BRCA2 was recapitulated in clonogenic assays
in which cells were exposed to the drug for only 24 hr
(Figure S2D).
BRCA2 plays a central role in HR repair by recruiting RAD51 to
the sites of DSBs ssDNA present at stalled replication forks to
initiate strand-invasion reactions. We therefore investigated
whether RAD51 deficiency sensitized cells to G4-interacting
compounds, similarly to loss of BRCA2. Indeed, exposure to
PDS caused a substantial drop in cell viability of HEK293T cells
lacking RAD51 compared to control cells (Figures 3C and S2C).
Olaparib reduced the viability of RAD51-depleted cells; however,452 Molecular Cell 61, 449–460, February 4, 2016 ª2016 The Authorit also exhibited toxicity against control cells (Figure 3D). More-
over, RAD51 depletion sensitized HEK293T cells to theG4 ligand
PhenDC (Figure 3E; Piazza et al., 2010). In western blot analyses
(Figure 3F), PDS and PhenDC both induced apoptosis specif-
ically in RAD51-deficient cells, detected by cleaved PARP1
and gH2AX expression, a well-established marker for DNA dam-
age that is also induced by apoptosis (Rogakou et al., 2000).
Thus, treatment with G4-interacting agents elicits DNA damage
leading to specific killing of cells lacking BRCA2 or RAD51.While
PhenDC drastically reduced viability of Brca1/ mouse tumor-
derived cells (Figure S2E), its toxicity against BRCA2-deficient
V-C8 cells was rather modest (Figure S2A).s
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Figure 4. Elevated Levels of DNADamage in
RAD51-Deficient Human Cells Treated with
PDS
(A) Representative images of HEK293T cells
transfected with control or RAD51 siRNA and
treated with PDS for 4 days before processing for
immunofluorescence staining with anti-gH2AX
antibody (green). DNA was counterstained with
DAPI (blue).
(B) Quantification of the frequency of cells withR5
gH2AX foci treated as in (A); n = 3; error bars, SD. p
values were calculated using an unpaired two-
tailed t test (*p% 0.05; **p% 0.01).
(C) Representative images of cells treated as in (A)
processed for comet assays. Scale bar, 50 mm.
(D) Quantification of tail moment using comet
assays of cells treated as in (A); n = 3; error bars,
SD. p values were calculated using an unpaired
two-tailed t test (*p% 0.05).
(E) Representative images of FISH analysis of
metaphase chromosome spreads of cells treated
as in (A) with a Cy3-conjugated telomeric probe
(red). DNA was counterstained with DAPI (blue).
Arrowheads point to chromatid/chromosome
breaks.
(F) Quantification of mean DSB frequencies (red
bars) in cells treated as in (A). Approximately 40
metaphases were analyzed for each sample. See
also Figure S3.PDSEnhancesDNADamage Levels in HR-Compromised
Cells
We next focused on understanding the mechanism underlying
the impaired viability of RAD51-deficient cells in the presence
of PDS. Quantification of gH2AX foci as detected by immunoflu-
orescence staining (Figures 4A and S3A) revealed a significant
increase in the frequency of HR-deficient cells containing
gH2AX foci in response to PDS (Figure 4B). On average,
16.5% of untreated RAD51-depleted cells exhibited five or
more gH2AX foci, which escalated to 37.3% and 55.4%
following treatment with 2 or 10 mM PDS, respectively. In control
cells, the focal gH2AX accumulation upon PDS treatment was
not statistically significant (from 4.5% to 8.2% and 9.7%). Alka-
line comet assays, in which the percentage of tail DNA relative to
total DNA was indicative of the levels of DNA damage present inMolecular Cell 61, 449–460an individual cell (Figure 4C), confirmed
that PDS-triggered DNA damage was
significantly augmented in HR-deficient
compared to HR-proficient cells (Fig-
ure 4D). In agreement with this, PDS eli-
cited increased numbers of DBSs per
metaphase in control cells, and RAD51
depletion further enhanced this effect
(Figures 4E, 4F, and S3B). In these im-
ages we used telomeric FISH probes
that helped define individual chromo-
somes. Given the reduced intensity of
the FISH signal for the telomeric G-rich
strand in PDS-treated samples, we
increased acquisition time for these im-ages, as described for Figure 2B. The average number of breaks
detected in this assay reflects break accumulation in mitosis,
while cells with higher levels of DNA damage most likely arrest
during G2/M transition. Consistently, PDS treatment and
RAD51 depletion caused a decrease in the mitotic index (Fig-
ure S3C). Taken together, these data supported the concept
that G4 stabilization triggers DNA damage, with lethal conse-
quences in cells with compromised capacity for HR-mediated
repair.
Acute Replication Stress Induced by PDS in Cells
Lacking RAD51 or BRCA2
PDS has been proposed to induce replication-dependent DNA
damage (Rodriguez et al., 2012). This prompted us to monitor
the assembly of replication protein A (RPA) subnuclear foci, February 4, 2016 ª2016 The Authors 453
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Figure 5. PDS Exacerbates the Replication
Defect of RAD51- and BRCA2-Deficient Hu-
man Cells.
(A) Representative images of HEK293T cells
transfected with control or RAD51 siRNA and
treated with PDS for 4 days before processing for
immunofluorescence staining with anti-RPA anti-
body (green). DNA was counterstained with DAPI
(blue).
(B) Quantification of the frequency of cells with
R10 RPA foci treated as in (A); n = 3; error bars,
SD. p values were calculated using an unpaired
two-tailed t test (*p% 0.05; **p% 0.01).
(C) HEK293T cells transfected with control or
RAD51 esiRNA were processed for DNA fiber
analysis as outlined in the inset, followed by
quantification of the frequency of newly fired
origins (n = 2; error bars, SD). p values were
calculated using an unpaired two-tailed t test
(*p% 0.05).
(D) Quantification of the relative replication tract
length (IdU/CldU) in cells treated as in (C). Middle
line represents median, and the box extends from
the 25th to 75th percentiles. The whiskers mark the
10th and 90th percentiles. p values were calculated
using a Mann-Whitney test (n = 2; ****p < 0.0001).
(E) DLD1 cells, BRCA2 proficient (+BRCA2) or
deficient (BRCA2), were processed for DNA fiber
analysis as outlined in the inset, followed by
quantification of the frequency of newly fired
origins (n = 2; error bars, SD). p values were
calculated using an unpaired two-tailed t test
(*p% 0.05).
(F) Quantification of the relative replication tract
length (IdU/CldU) in cells treated as in (E). Middle
line represents median, and the box extends from
the 25th to 75th percentiles. The whiskers mark the
10th and 90th percentiles. p values were calculated
using a Mann-Whitney test (n = 2; ****p < 0.0001).
See also Figure S4.(Figures 5A and S4A) as a readout for genome-wide ssDNA
accumulation. PDS induced an approximately 6-fold increase
in the levels of RPA foci in control cells and approximately
12-fold increase in RAD51-deficient cells (Figure 5B). RPA accu-
mulation on the chromatin, together with elevated frequency of
origin firing and reduced replication rates, represents signatures
of replicative stress (Zeman and Cimprich, 2014). To define
the nature of this replication defect, we performed DNA fiber
analyses in which replication tracks were labeled with consecu-
tive 30 min pulses of CldU and IdU. Addition of PDS during the454 Molecular Cell 61, 449–460, February 4, 2016 ª2016 The Authorssecond pulse enabled us to evaluate the
immediate effect of G4 stabilization on
replication. Relative tract length was
decreased significantly in PDS-treated
cells compared to untreated cells, an ef-
fect that was more prominent in cells
lacking RAD51 or BRCA2 expression
(Figures 5D, 5F, S4B, and S4C). PDS
may induce persistent G4s that reduce
replication rate or cause DNA breakagethat obstructs replication fork progression. Possibly as a
compensatory mechanism, PDS treatment significantly
increased the number of newly fired origins, detected as green
tract only, specifically in RAD51- (Figure 5C) or BRCA2-deficient
cells (Figure 5E). Notably, elevated origin firingwas also detected
in untreated HR-deficient cells. Thus, the replication stress
endogenous to HR-compromised cells may be potentiated by
chemical G4 stabilization to levels that become lethal. To test
this possibility, we used aphidicolin as an alternative means to
elicit replication stress (Figure S4D). Treatment with a nontoxic
A B
C D E
Figure 6. Effect of PDS on Viability of
BRCA2-Deficient Cells and Tumors
(A) DLD1 cells, BRCA2 proficient (+BRCA2) or
deficient (BRCA2), were incubated with 2 mM
PDS. Whole-cell extracts (WCE) or chromatin
fractions prepared at indicated time points were
immunoblotted as shown.
(B) Cells treated as in (A) were processed for FACS
analyses of DNA content after 48 hr. Quantification
of the percentage of cells in G2/M is shown (n = 3;
error bars, SD). p values were calculated using an
unpaired two-tailed t test (***p % 0.001; ****p %
0.0001).
(C) Clonogenic survival assays of DLD1 cells,
BRCA2 proficient (+BRCA2) or deficient
(BRCA2), exposed to the indicated concentra-
tions of RHPS4 for 24 hr. Error bars represent SD of
triplicate values obtained from a single experiment.
(D and E) Mean tumor weights in untreated and
RHPS4-treated mice injected with BRCA2-profi-
cient (+BRCA2; D) or deficient (BRCA2; E) DLD1
cells (n = 8; error bars, SD). Tumor weight inhibition
(TWI) was calculated at the time point of maximum
effect. See also Figures S5 and S6.dose of aphidicolin led to sensitization of BRCA2-proficient cells
to PDS. The synergy between the two compounds was not
observed in BRCA2-deficient cells. This suggested that
BRCA2 abrogation and aphidicolin treatment cause equivalent
levels of replication stress and DNA damage, leading to compa-
rable outcomes in the context of G4 stabilization by PDS.
PDS Triggers Checkpoint Activation and G2/M Arrest
in HR-Defective Cells
Given the profound antiproliferative effect of PDS in BRCA2- or
RAD51-deficient cells, we examined its impact on the DNA dam-
age response (DDR). In cells lacking BRCA2 or RAD51 expres-
sion, continuous PDS treatment for 4 days elicited a robust
phosphorylation of KAP1 (Ser824), CHK1 (Ser314/345), and
RPA (Ser4/8), indicative of ATM/ATR checkpoint activation, as
well as PARP1 cleavage, a marker for apoptosis (Figures S5A
and S5B). To establish whether DDR preceded apoptosis onset,
we monitored the response to PDS over a 48 hr interval. In
BRCA2-deficient cells, PDS triggered H2AX and CHK1 phos-
phorylation after 8 hr of treatment, whereas PARP1 cleavage
was initiated between 24 hr and 48 hr (Figure 6A). RAD51-
depleted HEK293T cells similarly exhibited gH2AX activation
prior to PARP1 cleavage (Figure S5C). These results indicate
that PDS-induced DDRs are provoked prior to apoptosis in cells
lacking BRCA2 or RAD51. Accordingly, BRCA2- and RAD51-
deficient cells accumulated in G2/M after PDS treatment (Fig-
ures 6B and S6A). A decrease in S-phase cells further reflected
the effect of PDS on cell-cycle progression and checkpoint
activation specifically in HR-deficient cells (Figures S6A and
S6B). PDS induces replication-associated DSBs, although tran-
scription-related DNA damage may accumulate in stages of the
cell cycle other than S phase (Rodriguez et al., 2012). To address
whether PDS causes damage in noncycling cells, G0/G1 arrestMowas induced by serum starvation in the presence or absence
of PDS. Arrested cells lacked the ability to incorporate the thymi-
dine analog EdU, in contrast to cells released into the cell cycle
by serum addition to the media (Figure S6C). Quantification of
gH2AX-positive cells demonstrated that PDS treatment for
48 hr did not induce DNA damage in noncycling cells, while a
marked increase in the percentage of cells expressing gH2AX
was detected in the subset of cycling cells treated with PDS
(Figure S6C).
In Vivo Responses of BRCA2-Deficient Tumors
to G4 Ligands
Regardless of the effective suppression of HR-deficient cell
viability and survival by PDS-mediated G4 stabilization (Figures
3A and S2D), the efficacy of PDS could not be established in vivo
due to its toxicity predicted by in vitro studies (Rodriguez et al.,
2012). Instead, we tested in our cellular models a previously re-
ported G4-stabilizing drug, RHPS4 (Gavathiotis et al., 2003;
Gowan et al., 2001; Heald et al., 2002), with well-characterized
pharmacological features (Leonetti et al., 2008; Salvati et al.,
2007). RHPS4 markedly diminished survival of BRCA2-deficient
DLD1 cells relative to BRCA2-proficient cells (Figure 6C). To test
its efficacy in vivo, DLD1 cells were injected into mice and al-
lowed to form palpable tumors. In line with previous publications
reporting the antitumor effect of RHPS4 (Leonetti et al., 2008;
Salvati et al., 2007), this drug repressed growth of BRCA2-profi-
cient tumors as assessed by tumor weight inhibition (TWI) (22%,
Figure 6D). Importantly, the growth inhibitory effect of RHPS4
was almost twice as pronounced in BRCA2-deficient tumors
(TWI = 41%, Figure 6E). RHPS4 treatment elicited a marked
delay in tumor regrowth (approximately 7 days in BRCA2-defi-
cient compared to 4 days in BRCA2-proficient tumors). Thus,
our conclusions based on cellular models can be translatedlecular Cell 61, 449–460, February 4, 2016 ª2016 The Authors 455
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mouse tumor-derived cell lines Figure 7. Olaparib-Resistant Brca1-Deleted
Tumor Cells Exhibit PDS Sensitivity
(A and B) Dose-dependent viability assays of
mousemammary tumor-derived cell lines deficient
in REV7 (A) or 53BP1 (B) treated with indicated
concentrations of PDS or olaparib. Graphs shown
are representative of at least two independent
experiments, each performed in triplicate. Error
bars represent SD of triplicate values obtained
from a single experiment.
(C) Representative images of cells described in (A)
incubated with 0.5 mM olaparib (OLAP), PDS for
40 hr, or irradiated with 10 Gy of IR followed by 1 hr
recovery and processed for immunofluorescence
staining with anti-RAD51 antibody (green). DNA
was counterstained with DAPI (blue).
(D) Quantification of the frequency of cells withR5
RAD51 foci in cells treated as in (C); n = 2; error
bars, SD; >200 nuclei were analyzed for each
condition per replica. See also Figure S7.in vivo and support the concept that G4-stabilizing compounds
identify a class of drugs, whichmay facilitate future development
of novel therapeutic strategies for targeting BRCA2-deficient
tumors.
PDS Kills Olaparib-Resistant Tumor-Derived Cells
Treatment of BRCA-deficient tumors poses a major challenge
in the clinic due to the rapid emergence of drug resistance. To
test the potential of PDS to eliminate Brca1-deficient mouse
tumor-derived cells refractory to olaparib, we used two
Brca1/ cellular mouse models, in which olaparib resistance
was mediated by concomitant loss of REV7 (Figure 7A; Xu
et al., 2015) or 53BP1 (Figure 7B; Jaspers et al., 2013). Cells car-
rying intact Brca1 (Brca1+/+) showed no sensitivity to PDS or
olaparib, while cells established from a Brca1/ tumor were
sensitive to both drugs, as determined in viability and clonogenic
assays (Figures 7A, 7B, S7A, and S7B). Strikingly, olaparib-resis-
tant Brca1-deficient cells lacking REV7 or 53BP1 expression
(Brca1/ shREV7; Brca1/ 53BP1-deficient) were hypersensi-
tive to PDS (Figures 7A, 7B, S7A, and S7B). These effects were
recapitulated in human cells, in which 53BP1 and BRCA1 were
depleted using siRNA (Figure S7C). Our results, therefore,
strongly suggest that BRCA1-deficient cells, including those
resistant to PARP inhibitors, can be targeted by treatment with
G4-stabilizing compounds.
HR restoration in Brca1-deleted cells and tumors is driven by
53BP1 loss, which enables survival (Bouwman et al., 2010; Bun-
ting et al., 2010). Moreover, ionizing radiation (IR)-induced
RAD51 foci assemble in olaparib-resistant Brca1/, 53BP1-
deficient cells (albeit not at the same level as in Brca1+/+ cells),
but not in olaparib-sensitive Brca1/ tumor-derived cells (Jas-
pers et al., 2013). Our data (Figures 7C and 7D) demonstrate456 Molecular Cell 61, 449–460, February 4, 2016 ª2016 The Authorsthat olaparib treatment itself triggers
RAD51 foci in wild-type and olaparib-
resistant, but not olaparib-sensitive,
cells, thereby providing a direct correla-
tion between olaparib-induced HR reacti-vation and its impact on cell survival. PDS treatment induced
RAD51 foci in Brca1+/+ cells, similarly to olaparib (Figures 7C
and 7D). However, RAD51 foci were absent in both olaparib-
sensitive and olaparib-resistant cells upon treatment with PDS
(Figures 7C and 7D), suggesting that failure to reactivate HR
repair contributes to the toxicity of this compound in Brca1/,
53BP1-deficient cells. To gain further insight into the mecha-
nism of RAD51 foci suppression, we evaluated the levels of
chromatin-associated RPA, indicative of end resection activity.
In the chromatin fraction of PDS-treated cells, less RPA was de-
tected than in cells exposed to olaparib or IR (Figure S7D). Thus,
impaired HR reactivation upon PDS treatment in a Brca1/,
53BP1-deficient background is likely caused by defects in end
resection.
DISCUSSION
The ability of G-rich DNA to adopt G4 secondary structures
in vitro was reported over 50 years ago (Gellert et al., 1962).
Although G4s are thought to positively regulate key cellular pro-
cesses, they can also obstruct replication-fork progression,
leading to genomic instability (Tarsounas and Tijsterman,
2013). In this study, we establish that effective replication of
G4 structures requires HR activities. G4s represent potent
replication barriers, andHR provides awell-characterizedmech-
anism for replication-fork restart and repair of replication-associ-
ated DSBs. Yet, the potential requirement for HR in G4 stability
has not been investigated, with the notable exception of Saccha-
romyces cerevisiae pif1 mutants, in which attempts to restart
forks stalled in the vicinity of G4 structures generated recombi-
nation intermediates. This suggested a role for HR in fork restart
when Pif1 activity is abrogated (Ribeyre et al., 2009).
HR Is Required for Effective Replication of Genomic
Regions with G4-Forming Potential
HR factors have previously been implicated in telomere mainte-
nance (Tacconi and Tarsounas, 2015). In the present work, we
used a plasmid-based replication assay in human cells to
show that replication of telomeric repeats is ineffective when
key HR activities are abrogated. Two lines of evidence estab-
lished the HR requirement for replication of the G-rich telomeric
strand. First, telomere fragility triggered by HR gene deletion
was specific to the G-rich telomeric strand, which possesses
G4-forming potential. Second, disruption of the G4-forming telo-
meric repeats through G-to-C substitutions rescued its replica-
tion defect in HR-deficient cells.
We propose that HR promotes replication in the presence of
obstructive G4 structures by restarting stalled forks and/or by re-
pairing replication-associated DSBs within telomeres, rather
than contributing to telomeric G4 dissolution per se. The latter
process is likely mediated by the shelterin component TRF1,
which recruits BLM helicase to telomeres to unwind G4 struc-
tures (Zimmermann et al., 2014). The concept that HR and
shelterin provide distinct mechanisms for telomere replication
is supported by the synthetic lethality observed between Brca2
and Trf1 gene deletions in immortalized MEFs, accompanied
by additive levels of telomere fragility (Badie et al., 2010). Inhibi-
tion of BLM expression with shRNA in Brca2-deleted cells simi-
larly induced cell-cycle arrest (J.Z. and M.T., unpublished data),
further arguing that independent mechanisms act during telo-
mere replication to dismantle G4s and to repair the DNA damage
induced by persistent G4 structures.
Importantly, G4 stabilization by PDS reduced viability of
mouse, human, and hamster cells lacking BRCA1, BRCA2, or
RAD51. It exacerbated telomere fragility and DNA damage levels
in HR-deficient cells. Conceivably, unresolved G4s presenting
intrachromosomally or within telomeres are converted to DSBs,
eliciting in turn checkpoint activation, cell-cycle arrest, and/or
specific elimination of HR-compromised cells by apoptotic
mechanisms.
The efficacy of PDS in cell killingwaspreviously attributed to its
genome-wide toxicity, suggested by the accumulation of DNA
damage marker gH2AX at genomic sites with computationally
inferred G4-forming sequences (Rodriguez et al., 2012). It is
conceivable that the same sites may be prone to breakage in
HR-deficient cells treated with PDS. Our mitotic DSB quantifica-
tion illustrates the additive effect of PDS on the levels of DNA
damage triggered by HR abrogation itself. A conundrum posed
by this quantificationwas that PDS induced approximately fifteen
DSBs per metaphase in cells lacking RAD51, yet in silico predic-
tions suggested thatmore than 300,000 genomic sites can adopt
G4 configurations (Huppert and Balasubramanian, 2005). This
discrepancy could be explained by the multitude of mechanisms
known to maintain genome integrity by dismantling G4s formed
during genome replication (Tarsounas and Tijsterman, 2013).
While most genomic G4s are dissolved by alternative mecha-
nisms, our data suggest that a subset triggers fork stalling and
DSBs, which are particularly toxic in HR-deficient cells lacking
a key pathway of fork restart and break repair. G4-induced
DNA damage may be repaired by error-prone mechanisms in
the absence of HR, which seems insufficient for the survival ofMothese cells. Moreover, checkpoint activation prevented entry of
cells with elevated DSB levels into mitosis, which further justifies
the lower number of mitotic DSBs detected in our assay.
Implications for Cancer Therapies
The work presented here demonstrates that the G4-stabilizing
drug RHPS4 limits the growth of BRCA2-deficient tumors
grafted in mice. The well-characterized ability of RHPS4 to
trigger telomere dysfunction may contribute to its toxicity to
BRCA2-deficient cells (Salvati et al., 2007). Therefore, we pro-
pose that the anticancer potential of the G4-stabilizing drug
RHPS4 can be exploited in the clinic for specific targeting of
BRCA2-deficient tumors. This tumor subset is likely to benefit
most from this novel class of anticancer drugs. Furthermore,
these results open a favorable prospective for future clinical
development of PDS into a drug-like compound, with a more
robust anticipated antitumor activity than RHPS4 in models for
BRCA2 inactivation.
Mutations in HR genes such as BRCA1, BRCA2, or RAD51C
predispose individuals to breast and ovarian cancers. Tumors
carrying HR gene deletions are vulnerable to drugs that either
introduce replication-associated DNA damage (e.g., platinum
drugs) or inhibit DNA repair pathways other than HR (e.g.,
PARP1 inhibitors, such as olaparib). In both cases, excessive
DNA-damage accumulation triggers cell death. Here, we pro-
pose that G4-binding compounds identify a novel class of mole-
cules that can be used to target BRCA deficiency. They act by
stabilizing secondary structures in genomic regions with high
G-rich content, thus reducing replication fork speed and inducing
RPA foci indicative of ssDNA accumulation. BRCA gene abroga-
tion is associatedwith the same responses (Carlos et al., 2013). In
the absence of HR, G4-interacting compounds are likely to
elevate the endogenous replication stress to levels that become
lethal due to excessive DNA-damage accumulation.
One well-documented caveat of targeted drug treatments,
such as olaparib, is that tumors rapidly acquire resistance
through mechanisms that include activation of P-glycoprotein
drug efflux transporter, genetic Brca1/2 re-activation, and loss
of 53BP1/REV7 (Bouwman and Jonkers, 2014; Jaspers et al.,
2013; Xu et al., 2015). In this work, we establish that G4-stabiliz-
ing compounds are profoundly toxic to BRCA-defective cells,
including those resistant to PARP inhibitors. In particular, the
striking cytotoxicity of PDS is due to the combined replication
failure induced by this drug and the DNA repair defect associ-
ated with HR abrogation. Therefore, pharmacological G4
stabilization could be exploited in future therapeutic modalities
targeting this difficult to treat tumor subset. Olaparib-resistant
cells fail to reactivate HR in response to PDS, whichmay account
for the lethality induced by this G4-stabilizing compound.
We therefore anticipate that further clinical development of
G4-stabilizing compounds will enhance their ability to selectively
eliminate HR-compromised tumors, including those that have
acquired resistance to existing therapies.
EXPERIMENTAL PROCEDURES
For detailed descriptions of these and additional procedures, see Supple-
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Cell Lines, Culture Conditions, and In Vivo Experiments
HEK293T, H1299, and DLD1 cells were cultured under conventional growth
conditions. In vivo experiments were performed as previously described
(Salvati et al., 2007). All animal procedures were in compliance with the na-
tional and international directives (D.L. March 4, 2014, no. 26; directive
2010/63/EU of the European Parliament and of the council; Guide for
the Care and Use of Laboratory Animals, United States National Research
Council, 2011).
Plasmid-Based Replication Assay
Plasmid-based replication assays were performed as previously described
(Sarkies et al., 2010; Szu¨ts et al., 2008) with modifications listed in Supple-
mental Experimental Procedures.
RNAi
DLD1 and HEK293T cells were transfected with 40 nM siRNA using Dharma-
fect 1 (Dharmacon) according to manufacturer’s instructions.
Cell Viability Assays
Cell viability was determined by incubation with 10 mg/ml of resazurin for 2 hr.
Fluorescence was measured at 590 nm using a plate reader (POLARstar,
Omega one). Cell viability was expressed relative to untreated cells of the
same cell line, thus accounting for any differences in viability caused by HR
deficiency. Graphs shown are representative of at least two independent ex-
periments, each performed in triplicate. Error bars represent SD of triplicate
values obtained from a single experiment.
FACS Analysis
Cells were harvested by trypsinization, washed in cold PBS, and fixed in ice-
cold 70% ethanol overnight at 4C. Following two washes in PBS, cells were
incubated with 20 mg/ml propidium iodide and 10 mg/ml RNase A (Sigma) in
PBS. At least 10,000 cells were analyzed by flow cytometry (Becton Dickin-
son). Data were processed using CellQuest (Becton Dickinson) and ModFit
LT software.
Alkaline Single-Cell Gel Electrophoresis Comet Assay
Thecometassaywasperformedaspreviouslydescribed (Singh et al., 1988). Tail
measurement was performed using the Komet 5.5 image analysis software.
Immunofluorescence
Cells were subjected to immunofluorescence staining as described (Tarsou-
nas et al., 2004).
Preparation of Metaphase Spreads and Telomere FISH
Metaphase spread preparation and telomeric FISH were performed as previ-
ously described (Badie et al., 2015).
Chromosome Orientation FISH and IF-FISH
For CO-FISH, cells were plated at 50%–60% confluency and treated with
10 mM bromodeoxyuridine (BrdU) for 20 hr. Colcemid (0.2 mg/ml) was added
to the cells 4–6 hr before metaphases were processed for CO-FISH as previ-
ously described (Bailey et al., 2001).
For IF-FISH, metaphases were spun onto coverslips using a cytospin appa-
ratus (Cytospin 4, Fisher) and subjected to immunofluorescence staining as
described (Tarsounas et al., 2004). Samples were fixed again in 4% parafor-
maldehyde in PBS, and FISH was performed as described (Tarsounas et al.,
2004) using 15 mg/ml Cy3-conjugated (CCCTAA)6-PNA telomeric probe
(Applied Biosystems).
DNA Fiber Assay
DNA fiber assays were performed as described previously (Jackson and
Pombo, 1998).
Immunoblotting
SDS-PAGE and immunoblotting were performed as previously described
(Badie et al., 2015). See Supplemental Experimental Procedures for antibodies
used in this study.458 Molecular Cell 61, 449–460, February 4, 2016 ª2016 The AuthorSUPPLEMENTAL INFORMATION
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